and Richard P. Cambria, MD, FACS 2 In this issue of Angiology, Bissacco et al evaluate the evolution of best medical treatment (BMT) in patients admitted for carotid endarterectomy (CEA) in their center over a 13-year period. 1 Prescription of acetylsalicylic acid, clopidogrel, statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and b-blockers increased considerably during the study period. The most impressive increase (>60%) was in the prescription rates of statins (from 11.6% in 2002 to 72.4% in 2014). The evidence regarding statin use in patients with carotid stenosis has emerged some years ago. 2 Statins reduce stroke risk and improve both short-and long-term outcomes in patients undergoing CEA and carotid artery stenting (CAS). [2] [3] [4] [5] There are also additional aspects to consider to improve outcomes, such as statin loading peri-intervention (CEA and CAS). 6, 7 The authors should be congratulated for their effort to apply BMT. 1 Some aspects of this study deserve some comments.
Differences in the Management of Asymptomatic and Symptomatic Patients with Carotid Stenosis
The authors state that "while there is broad consensus that symptomatic patients should undergo expedited surgery, the advantages of CEA for asymptomatic patients are less certain." 1 Indeed, the vast majority of contemporary guidelines recommend CEA within 2 weeks of symptoms as the treatment of choice for the management of patients with symptomatic carotid artery stenosis. 8 Some guidelines (eg, the European Society for Vascular Surgery guidelines published in 2009) [9] [10] [11] also recommend CEA for asymptomatic carotid stenosis (ACS), but this is usually a weaker recommendation. The initiation of BMT is recommended for all patients with ACS, [8] [9] [10] [11] regardless of whether these patients will eventually undergo CEA. A skeptical reader could argue: "If the benefit of CEA in patients with ACS is currently not firmly established, why were almost 80% of the patients undergoing CEA in this study 1 asymptomatic? Why were they not offered BMT instead of CEA?"
The most likely reason is that this study was performed from 2002 to 2014. 1 The concept that most patients with ACS should not be offered CEA routinely but may be best managed by BMT alone was first reported in 2009. 12 Until then, it was routine practice to offer CEA for carotid artery stenosis, whether symptomatic or not.
12, 13 The authors should be congratulated for their honesty in reporting their findings.
Differences in Outcomes Between CEA and BMT in Asymptomatic Patients with Carotid Stenosis
The authors also support that "Although surgical technique has remained substantially unaltered, medical therapy has changed considerably in recent years."
1 The 2 landmark randomized controlled trials that initially suggested the preference of CEA over only BMT for patients with ACS were the Asymptomatic Carotid Atherosclerosis Study (ACAS) 14 in 1995 and the Asymptomatic Carotid Surgery Trial (ACST) 15 in 2004. In ACAS (1995), 14 the estimated 5-year percentage of "any perioperative stroke or death" in the group undergoing CEA was 12.4%. In the ACST (published 9 years later), the 5-year stroke risk in patients undergoing CEA was 6.4% while the 30-day stroke/death rate was 3.1%. 15 More recently, a registry of CEA procedures performed between 2005 and 2010 (n ¼ 48 185 CEA procedures) from 9 national/regional vascular registries (Australia, Denmark, Finland, Hungary, Italy, Norway, Sweden, Switzerland, and the United Kingdom) showed that CEA was performed in patients with ACS with overall combined 30-day stroke/death rates of 0.9% ranging from as low as 0.5% in Italy to 2.7% in Sweden. 16 These results are difficult to interpret because of the differences in patient selection, trial design, and multiple end point definitions. However, it appears that there has been an improvement in CEA results. This may have resulted from refinements of surgical techniques, different patient selection criteria, and improvements in BMT.
Best Medical Treatment: A Sine Qua Non in the Management of Patients With ACS
Nobody disputes that all patients with ACS (and symptomatic) should receive current BMT to reduce the incidence not only of cerebrovascular (eg, stroke and transient ischemic attack [TIA] episodes) but also of cardiovascular events (eg, myocardial infarction and cardiac death). 17 A more relevant question to ask, however, is: "Should all patients with ACS only be offered BMT, or are there some patients with ACS who will benefit from additional prophylactic CEA?" This appears to be the "Eris Golden Apple of Discord" (or the "bone of contention") in the management of ACS. 18 In other words, although all patients with ACS should be offered BMT, some patients with ACS are at higher stroke risk and could therefore potentially benefit from additional prophylactic CEA to avoid becoming symptomatic. 18 The exact percentage of patients with ACS who should be offered prophylactic CEA is not known. Several criteria and parameters have been proposed to identify these high-risk individuals, such as microemboli detection by transcranial Doppler, identification of the unstable carotid plaque using ultrasound, a reduced cerebral blood reserve, intraplaque hemorrhage on magnetic resonance imaging (MRI), silent embolic infarcts on brain MRI or computed tomography, and so on. 18 Another concept to consider is that BMT alone may not be adequate for the prevention of disease progression and the development of symptoms in all patients. A study from Boston, Massachusetts including 794 patients (n ¼ 900 carotid arteries) demonstrated that BMT alone failed to prevent carotid disease progression in 40% and the development of ipsilateral neurologic symptoms in 12% of patients with moderate (50%-69%) ACS over 5 years. 19 In a recent report from the largest prospective study involving patients with ACS undergoing medical intervention alone, the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) study, 20 1121 patients with 50% to 99% ACS were assigned to BMT and followed up for 6 to 96 months (mean: 48 months). During this time, 130 (11.6%) patients had a first ipsilateral cerebrovascular or retinal ischemic event. 20 The percentage of patients with ACS who developed ipsilateral neurologic symptoms despite receiving BMT in the study from Boston (12% over 5 years) 19 is very similar to the percentage of patients with ACS who developed ipsilateral neurologic symptoms on BMT in ACSRS (11.6% over 4 years). 20 These 2 independent studies 19, 20 show that the annual stroke risk for ACS on BMT is not 0.5% to 1% (as has been proposed), [21] [22] [23] but much higher (2.4% 19 -2.9% 20 ). The 0.5% to 1% stroke risk applies to patients with moderate carotid stenosis (*50%), 24 who would not be candidates for CEA anyway. Current guidelines only consider CEA in patients with ACS having severe (>70%) carotid stenosis 8, 9 ; those patients are at higher stroke risk with BMT alone. 24 A more recent study on 115 patients (126 carotid arteries) with severe (70%-89%; n ¼ 88) or very severe (90%-99%; n ¼ 38) ACS managed with BMT alone (usually because of comorbidities or patient preference) showed that during a mean follow-up of 27 months, almost a quarter of the patients (n ¼ 31; 24.6%) developed ipsilateral neurologic symptoms despite being on BMT. 25 This study showed that in a large percentage of patients with ACS having very severe stenosis, BMT alone fails to prevent the occurrence of ipsilateral neurologic symptoms, thus supporting the role of prophylactic CEA as recommended by many guidelines. 25 Another point to consider is that a TIA can occur during sleep and these patients continue to be considered as "asymptomatic". In 1998, it was estimated that approximately 770 000 people experienced a symptomatic stroke, whereas 11 million had an asymptomatic stroke. 26 Many of these asymptomatic strokes occurred as a result of emboli from ACS. By continuing to consider these patients as "asymptomatic" (and thus managing them with BMT alone and not offering CEA), there is a higher risk of stroke.
A comparison of current BMT versus CEA versus CAS is urgently needed. 27 However, participants must be willing to undergo randomization to a conservative (noninvasive) treatment (ie, BMT) for their carotid stenosis. The premature cessation of the Stent-Protected Angioplasty versus Carotid Endarterectomy 2 trial 28 suggests that it may be hard to convince patients not to take any action (ie, not to undergo CEA or CAS) to prevent a possible stroke from their carotid stenosis and just continue with BMT. One wonders what would the patients with ACS in the study by Bissacco et al 1 have said if they were offered only BMT instead of CEA.
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